HC #1
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HC #1 (HC #1).
Unknown
| Metabolism | Not characterized |
| Excretion | Renal: 90% as unchanged drug; fecal: 10%. |
| Half-life | 2–4 hours (terminal); prolonged in renal impairment. |
| Protein binding | 20–30% bound to albumin. |
| Volume of Distribution | 0.3–0.5 L/kg; indicates distribution into total body water. |
| Bioavailability | Oral: 80–90%. |
| Onset of Action | Oral: 30–60 min; IV: <5 min. |
| Duration of Action | Oral: 4–6 hours; IV: 2–4 hours. |
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No formal guidelines; monitor for increased systemic exposure in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Children: 1-2 mg/kg IV every 6 hours, not to exceed 100 mg per dose. |
| Geriatric use | No specific dose adjustment; monitor for adverse effects such as hyperglycemia and osteoporosis with prolonged use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HC #1 (HC #1).
| Breastfeeding | Unknown; M/P ratio not established. |
| Teratogenic Risk | HC #1 is not a recognized drug identifier. No teratogenic data available. |
| Fetal Monitoring | None specified. |
| Fertility Effects |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component"]
| Precautions | ["Not for clinical use"] |
Loading safety data…
| Unknown. |